LSP1 is a prognostic biomarker associated with apoptosis in acute myeloid leukemia

The leukocyte-specific protein 1 (LSP1) has been implicated in cancer progression, and this paper aims to reveal the prognostic value and pathogenic role of LSP1 in acute myeloid leukemia (AML). The TCGA and GTEx datasets were performed to assess the expression and prognostic significance of LSP1 in AML. qRT-PCR was utilized to detect LSP1 expression in AML patients. The impact of LSP1 knockdown on AML was assessed using CCK-8, 7-AAD/Annexin-V assays, and xenograft mouse models. Gene Set Enrichment Analysis (GSEA), qRT-PCR, and functional experiments were employed to explore and verify the potential signaling pathway of LSP1 in AML. Our findings revealed that a high expression level of LSP1 indicated poor prognosis for AML. Meanwhile, the knockdown of LSP1 could inhibit AML <i>in vitro</i> and <i>in vivo</i>. Next, we observed that the NF-κB signaling pathway, associated with anti-apoptotic effects, was significantly upregulated in the high LSP1 expression group, and knocking down LSP1 could inhibit it. In addition, we also found that the NF-κB pathway-related anti-AML effect of bortezomib partially relied on LSP1. This study revealed that LSP1 plays a crucial role in the progression of AML, indicating its potential as a prognostic biomarker and therapeutic target.